Advertisement

Molecular Medicine

, Volume 20, Supplement 1, pp S37–S42 | Cite as

Advances in Sickle Cell Therapies in the Hydroxyurea Era

  • Joshua J. Field
  • David G. Nathan
Retrospective

Abstract

In the hydroxyurea era, insights into mechanisms downstream of erythrocyte sickling have led to new therapeutic approaches for patients with sickle cell disease (SCD). Therapies have been developed that target vascular adhesion, inflammation and hemolysis, including innovative biologics directed against P-selectin and invariant natural killer T cells. Advances in hematopoietic stem cell transplant and gene therapy may also provide more opportunities for cures in the near future. Several clinical studies are underway to determine the safety and efficacy of these new treatments. Novel approaches to treat SCD are desperately needed, since current therapies are limited and rates of morbidity and mortality remain high.

Notes

Acknowledgment

This paper is dedicated to Dr. Anthony Cerami, founder of the journal Molecular Medicine and longtime friend and colleague.

References

  1. 1.
    Savitt TL, Goldberg MF. (1989) Herrick’s 1910 case report of sickle cell anemia: the rest of the story. JAMA. 261:266–71.CrossRefGoogle Scholar
  2. 2.
    Herrick JB. (1910) Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch. Intern. Med. 6:517–21.CrossRefGoogle Scholar
  3. 3.
    Pauling L, et al. (1949) Sickle cell anemia: a molecular disease. Science. 110:543–8.CrossRefGoogle Scholar
  4. 4.
    Platt OS, et al. (1991) Pain in sickle cell disease: rates and risk factors. N. Engl. J. Med. 325:11–6.CrossRefGoogle Scholar
  5. 5.
    Castro O, et al. (1994) The acute chest syndrome in sickle cell disease: incidence and risk factors: the Cooperative Study of Sickle Cell Disease. Blood. 84:643–9.PubMedGoogle Scholar
  6. 6.
    Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 84:363–76.CrossRefGoogle Scholar
  7. 7.
    Platt OS, et al. (1994) Mortality in sickle cell disease: life expectancy and risk factors for early death. N. Engl. J. Med. 330:1639–44.CrossRefGoogle Scholar
  8. 8.
    Scott RB. (1970) Health care priority and sickle cell anemia. JAMA. 214:731–4.CrossRefGoogle Scholar
  9. 9.
    Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. (2010) Improved survival of children and adolescents with sickle cell disease. Blood. 115:3447–52.CrossRefGoogle Scholar
  10. 10.
    Gaston MH, et al. (1986) Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N. Engl. J. Med. 314:1593–9.CrossRefGoogle Scholar
  11. 11.
    Charache S, et al. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 332:1317–22.CrossRefGoogle Scholar
  12. 12.
    Platt OS, et al. (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J. Clin. Invest. 74:652–6.CrossRefGoogle Scholar
  13. 13.
    Steinberg MH, et al. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 289:1645–51.CrossRefGoogle Scholar
  14. 14.
    Steinberg MH, et al. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am. J. Hematol. 85:403–8.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Steinberg MH. (1997) Determinants of fetal hemoglobin response to hydroxyurea. Semin. Hematol. 34:8–14.PubMedGoogle Scholar
  16. 16.
    Lanzkron S, Carroll CP, Haywood C Jr. (2013) Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 128:110–6.CrossRefGoogle Scholar
  17. 17.
    Xu J, et al. (2011) Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 334:993–6.CrossRefGoogle Scholar
  18. 18.
    Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. (2002) Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl. Acad. Sci. U. S. A. 99: 3047–51.CrossRefGoogle Scholar
  19. 19.
    Hebbel RP. (1997) Adhesive interactions of sickle erythrocytes with endothelium. J. Clin. Invest. 100:S83–6.PubMedGoogle Scholar
  20. 20.
    Hebbel RP, Osarogiagbon R, Kaul D. (2004) The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 11:129–51.CrossRefGoogle Scholar
  21. 21.
    Kaul DK, Hebbel RP. (2000) Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 106:411–20.CrossRefGoogle Scholar
  22. 22.
    Wallace KL, et al. (2009) NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood. 114:667–76.CrossRefGoogle Scholar
  23. 23.
    Tedder TF, Steeber DA, Chen A, Engel P. (1995) The selectins: vascular adhesion molecules. FASEB J. 9:866–73.CrossRefGoogle Scholar
  24. 24.
    Ley K, Laudanna C, Cybulsky MI, Nourshargh S. (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7:678–89.CrossRefGoogle Scholar
  25. 25.
    Chang J, et al. (2010) GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 116:1779–86.CrossRefGoogle Scholar
  26. 26.
    Matsui NM, et al. (2001) P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 98:1955–62.CrossRefGoogle Scholar
  27. 27.
    Matsui NM, Varki A, Embury SH. (2002) Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood. 100:3790–6.CrossRefGoogle Scholar
  28. 28.
    Embury SH, et al. (2004) The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood. 104:3378–85.CrossRefGoogle Scholar
  29. 29.
    Kutlar A, et al. (2012) A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am. J. Hematol. 87:536–9.CrossRefGoogle Scholar
  30. 30.
    Telen MJ. (2014) Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. Hematol. Oncol. Clin. North Am. 28:341–54.CrossRefGoogle Scholar
  31. 31.
    Bernini JC, et al. (1998) Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 92:3082–9.PubMedGoogle Scholar
  32. 32.
    Griffin TC, McIntire D, Buchanan GR. (1994) High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N. Engl. J. Med. 330:733–7.CrossRefGoogle Scholar
  33. 33.
    Quinn CT, et al. (2011) Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br. J. Haematol. 155:263–7.CrossRefGoogle Scholar
  34. 34.
    Brennan PJ, Brigl M, Brenner MB. (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13:101–17.CrossRefGoogle Scholar
  35. 35.
    Tupin E, Kinjo Y, Kronenberg M. (2007) The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5:405–17.CrossRefGoogle Scholar
  36. 36.
    Singh UP, Venkataraman C, Singh R, Lillard JW Jr. (2007) CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr. Metab. Immune Disord. Drug Targets. 7:111–23.CrossRefGoogle Scholar
  37. 37.
    Wallace KL, Linden J. (2010) Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 116:5010–20.CrossRefGoogle Scholar
  38. 38.
    Field JJ, et al. (2013) Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 121:3329–34.CrossRefGoogle Scholar
  39. 39.
    Field JJ, Nathan DG, Linden J. (2011) Targeting iNKT cells for the treatment of sickle cell disease. Clin. Immunol. 140:177–83.CrossRefGoogle Scholar
  40. 40.
    Field JJ, et al. (2013) A phase 1 single ascending dose study of NKTT120 in stable adult sickle cell patients [abstract]. Blood. 122:977.Google Scholar
  41. 41.
    Bertles JF, Milner PF. (1968) Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia. J. Clin. Invest. 47:1731–41.CrossRefGoogle Scholar
  42. 42.
    Mohandas N, Hebbel R. (1994) Pathogenesis of Hemolytic Anemia. In: Sickle Cell Disease: Basic Principles and Clinical Practice. Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds.) New York, Raven Press, pp. 327–334.Google Scholar
  43. 43.
    Reiter CD, et al. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 8:1383–9.CrossRefGoogle Scholar
  44. 44.
    Gladwin MT, et al. (2003) Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 107:271–8.CrossRefGoogle Scholar
  45. 45.
    Belcher JD, et al. (2006) Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J. Clin. Invest. 116:808–16.CrossRefGoogle Scholar
  46. 46.
    Belcher JD, et al. (2014) Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 123:377–90.CrossRefGoogle Scholar
  47. 47.
    Ghosh S, et al. (2013) Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J. Clin. Invest. 123:4809–20.CrossRefGoogle Scholar
  48. 48.
    Kato GJ, Gladwin MT, Steinberg MH. (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 21:37–47.CrossRefGoogle Scholar
  49. 49.
    Bunn HF, et al. (2010) Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 116:687–92.CrossRefGoogle Scholar
  50. 50.
    Gladwin MT, et al. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med. 350:886–95.CrossRefGoogle Scholar
  51. 51.
    Parent F, et al. (2011) A hemodynamic study of pulmonary hypertension in sickle cell disease. N. Engl. J. Med. 365:44–53.CrossRefGoogle Scholar
  52. 52.
    Machado RF, et al. (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 118:855–64.CrossRefGoogle Scholar
  53. 53.
    Schmidtko A, Tegeder I, Geisslinger G. (2009) No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci. 32:339–46.CrossRefGoogle Scholar
  54. 54.
    Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD. (2001) Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch. Pathol. Lab. Med. 125:1436–41.PubMedGoogle Scholar
  55. 55.
    Weil JV, et al. (1993) NHLBI Workshop Summary: Pathogenesis of lung disease in sickle hemoglobinopathies. Am. Rev. Respir. Dis. 148:249–56.CrossRefGoogle Scholar
  56. 56.
    Klings ES, et al. (2014) An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am. J. Respir. Crit. Care Med. 189:727–40.CrossRefGoogle Scholar
  57. 57.
    Johnson FL, et al. (1984) Bone-marrow transplantation in a patient with sickle-cell anemia. N. Engl. J. Med. 311:780–3.CrossRefGoogle Scholar
  58. 58.
    Walters MC, et al. (1996) Bone marrow transplantation for sickle cell disease. N. Engl. J. Med. 335:369–76.CrossRefGoogle Scholar
  59. 59.
    Bhatia M, Walters MC. (2008) Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant. 41:109–17.CrossRefGoogle Scholar
  60. 60.
    Hsieh MM, et al. (2009) Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361:2309–17.CrossRefGoogle Scholar
  61. 61.
    Srinivasan R, et al. (2006) Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br. J. Haematol. 133:305–14.CrossRefGoogle Scholar
  62. 62.
    Hsieh MM, et al. (2014) Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 312:48–56.CrossRefGoogle Scholar
  63. 63.
    Bolanos-Meade J, et al. (2012) HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 120:4285–91.CrossRefGoogle Scholar
  64. 64.
    Levasseur DN, et al. (2004) A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. J. Biol. Chem. 279:27518–24.CrossRefGoogle Scholar
  65. 65.
    Pawliuk R, et al. (2001) Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 294:2368–71.CrossRefGoogle Scholar
  66. 66.
    Pestina TI, et al. (2009) Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol. Ther. 17:245–52.CrossRefGoogle Scholar
  67. 67.
    Perumbeti A, et al. (2009) A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood. 114:1174–85.CrossRefGoogle Scholar
  68. 68.
    Chandrakasan S, Malik P. (2014) Gene therapy for hemoglobinopathies: the state of the field and the future. Hematol. Oncol. Clin. North Am. 28:199–216.CrossRefGoogle Scholar
  69. 69.
    Hanna J, et al. (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 318:1920–3.CrossRefGoogle Scholar
  70. 70.
    Townes TM. (2008) Gene replacement therapy for sickle cell disease and other blood disorders. Hematology Am. Soc. Hematol. Educ. Program. 2008:193–6.Google Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Medical Sciences InstituteBloodCenter of WisconsinMilwaukeeUSA
  2. 2.Department of MedicineMedical College of WisconsinMilwaukeeUSA
  3. 3.Dana-Farber Cancer InstituteBostonUSA
  4. 4.Boston Children’s HospitalBostonUSA
  5. 5.Harvard Medical SchoolBostonUSA

Personalised recommendations